Vanguard Capital Management
IOVA icon

Vanguard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Vanguard Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.7M Buy
18,204,248
+1,586,511
+10% +$6.03M ﹤0.01% 1710
2026
Q1 		$58.3M Buy
+16,617,737
New +$53.2M ﹤0.01% 1784

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 94.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's IOVA Position: Q2 2026 in Review

Vanguard Capital Management increased its Iovance Biotherapeutics (IOVA) stake by 9.5% in Q2 2026, buying an estimated $6.03M and bringing the position to 18,204,248 shares worth $75.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1710.

Vanguard Capital Management first reported a position in IOVA in Q1 2026 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Vanguard Capital Management held 18,204,248 shares of Iovance Biotherapeutics worth $75.7M as of Q2 2026.
  • Vanguard Capital Management bought 1,586,511 Iovance Biotherapeutics shares in Q2 2026, an estimated $6.03M.
  • Iovance Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1710 holding.
  • Vanguard Capital Management first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.